Open AccessBcar1/p130Cas Protein and Primary Breast Cancer: Prognosis and Response to Tamoxifen Treatment
Author(s) -
S. van der Flier,
Arend Brinkman,
Maxime P. Look,
Elisabath M. Kok,
Marion E. Meijer–van Gelder,
Jan G.M. Klijn,
Lambert C. J. Dorssers,
John A. Foekens
Publication year - 2000
Publication title -
journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/92.2.120
Subject(s) - breast cancer , tamoxifen , antiestrogen , oncology , medicine , metastatic breast cancer , cancer , cancer research
The product of the Bcar1/p130Cas (breast cancer resistance/p130Crk-associated substrate) gene causes resistance to antiestrogen drugs in human breast cancer cells in vitro. To investigate its role in clinical breast cancer, we determined the levels of Bcar1/p130Cas protein in a large series of primary breast carcinomas.